Table of Contents

02 Introduction

03 Key Insights

05 Employer Specialty Trend Forecast

07 Employer Traditional Trend Forecast

09 Key Condition Profiles

14 Medical Pharmacy Specialty Drug Management

18 Pipeline

19 Insights Through Innovation

EDITORIAL STAFF
Brooke Kachura
Director, Marketing

Stephanie Stevens, MPH
Senior Manager, Market Research

CONTRIBUTORS
Lori Bymark, MSIA
Senior Vice President, Advanced Analytics

Karim Prasla, PharmD, MS, BCPS
Vice President, Clinical Outcomes, Advanced Analytics, and Research

Kathleen Campagna, BSN, MS
Vice President, Business Development — Self-Funded

Neely Burkhardt
Vice President, Marketing

Troy Phelps
Senior Director, Drug Economics

Peter Lenar
Director, Business Development — Self-Funded

Kayla Hirsch
Director, Marketing

Katie Lockhart, MS
Senior Forecast Analyst, Drug Economics

©2018 Magellan Rx Management. Magellan Rx Management 2018 Employer Market Insights Report™ is published in conjunction with D Custom. All rights reserved. All trademarks are the property of their respective owners. The content — including text, graphics, images and information obtained from third parties, licensors, and other material (“content”) — is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Figures may be reprinted with the following citation: Magellan Rx Management Employer Market Insights Report™, ©2018. Used with permission.
Dive in and gain the following insights:

- Comprehensive forecasting for key areas of pharmacy trend and spend
- Effective cost management strategies to tackle these trends
- Pilots and partnerships that demonstrate an innovative approach to pharmacy management

Thank you for taking the time to review the new Employer Market Insights Report™!

**Mostafa Kamal**
Chief Executive Officer
Magellan Rx Management
Key Insights

**TOTAL DRUG COST**

Specialty drug costs on the pharmacy benefit are projected to reach close to 50% by 2020 (50% by 2021)

<table>
<thead>
<tr>
<th>Year</th>
<th>Specialty</th>
<th>Traditional</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>39%</td>
<td>61%</td>
</tr>
<tr>
<td>2018</td>
<td>43%</td>
<td>57%</td>
</tr>
<tr>
<td>2019</td>
<td>46%</td>
<td>54%</td>
</tr>
<tr>
<td>2020</td>
<td>48%</td>
<td>52%</td>
</tr>
</tbody>
</table>

**OVERALL COST TREND**

Decreased trend in 2019 and 2020 are primarily due to slower growth of specialty drugs

<table>
<thead>
<tr>
<th>Year</th>
<th>% Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>3.6%</td>
</tr>
<tr>
<td>2018</td>
<td>6.7%</td>
</tr>
<tr>
<td>2019</td>
<td>4.6%</td>
</tr>
<tr>
<td>2020</td>
<td>5.4%</td>
</tr>
</tbody>
</table>

**SPECIALTY COST PER CLAIM**

- 2008: $1,661
- 2012: $1,995
- 2016: $4,157
- 2020: $6,300

4X increase over 12 years

**NUMBER OF SPECIALTY DRUGS**

- 2008: 249
- 2012: 433
- 2016: 557
- 2020: 700

3X increase over 12 years
**Key Insights**

**Key Conditions Cost Trend**
*2017-2020*

Autoimmune: anti-inflammatory and diabetes will continue to be the two main conditions driving overall drug costs.

30-35% of total cost

![Autoimmune: Anti-Inflammatory and Diabetes](autoimmune.png)

**Specialty Pipeline Cost Trend**

By 2020, specialty pipeline drugs will continue to offer providers and patients more treatment options.

25% of the overall growth in total pharmacy costs will come from new specialty pipeline drugs

![Specialty Pipeline](pipeline.png)

**Survey Says**

**Medical Pharmacy Drug Trend**

Overall, 66% of employer group respondents observed a medical pharmacy trend between 1% and 10%.

![Medical Pharmacy Drug Trend](drug_trend.png)

**Medical Pharmacy Drug Spend**

Employer groups surveyed reported a medical pharmacy drug spend of less than $10 million.

2017

<table>
<thead>
<tr>
<th>Category</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than $10 million</td>
<td>90%</td>
</tr>
<tr>
<td>$10 million-$20 million</td>
<td>10%</td>
</tr>
</tbody>
</table>

![Medical Pharmacy Drug Spend](spend.png)

**Key Conditions Cost Trend**

*2017-2020*

Autoimmune: anti-inflammatory and diabetes will continue to be the two main conditions driving overall drug costs.

30-35% of total cost

![Autoimmune: Anti-Inflammatory and Diabetes](autoimmune.png)

**Specialty Pipeline Cost Trend**

By 2020, specialty pipeline drugs will continue to offer providers and patients more treatment options.

25% of the overall growth in total pharmacy costs will come from new specialty pipeline drugs

![Specialty Pipeline](pipeline.png)

**Survey Says**

**Medical Pharmacy Drug Trend**

Overall, 66% of employer group respondents observed a medical pharmacy trend between 1% and 10%.

![Medical Pharmacy Drug Trend](drug_trend.png)

**Medical Pharmacy Drug Spend**

Employer groups surveyed reported a medical pharmacy drug spend of less than $10 million.

2017

<table>
<thead>
<tr>
<th>Category</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than $10 million</td>
<td>90%</td>
</tr>
<tr>
<td>$10 million-$20 million</td>
<td>10%</td>
</tr>
</tbody>
</table>

![Medical Pharmacy Drug Spend](spend.png)
Overall costs increased 3.6% from 2016 to 2017. Of this growth, traditional drug costs declined by -1.8%, while specialty drug costs rose by 13.1% (see figure 1).

A review of the 2017 specialty trend drivers showed that 9.2% of the growth was driven by higher usage of specialty medications while 3.9% was driven by changes in cost (see figure 2).

Specialty drug costs are forecasted to continue to have double-digit growth rates through 2020; however, the growth rate is expected to slow down in 2019 and 2020 compared to 2018 (see figure 3).

The slowdown in specialty growth will be driven by:

- A decline in the amount and frequency of price increases for current specialty drugs over the next three years. For example, in 2016, the average wholesale price (AWP) per day for a specialty drug increased 7.6%, while in 2017 AWP increased 5.6%.
- The contracting hepatitis C market also has put downward pressure on the specialty market.
- It is forecasted that very few of the top specialty drugs will be significantly challenged by either loss of patent protection or biosimilars in the next three years.

1. Utilization divided into consumers (utilizers) and consumption (supply per utilizer); Cost divided into cost share (patient pay), pricing (effective AWP discount), inflation (AWP change), and drug mix (market share).
**Employer Specialty Trend Forecast**

**FIGURE 4**

**Key Specialty Conditions Trend**

<table>
<thead>
<tr>
<th>Condition</th>
<th>2017 % of Total Cost</th>
<th>2018 % of Total Cost</th>
<th>2019 % of Total Cost</th>
<th>2020 % of Total Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUTOIMMUNE: Anti-Inflammatory</td>
<td>15.6%</td>
<td>16.6%</td>
<td>14.7%</td>
<td>12.8%</td>
</tr>
<tr>
<td>Oncology</td>
<td>5.9%</td>
<td>20.8%</td>
<td>16.2%</td>
<td>10.5%</td>
</tr>
<tr>
<td>Multiple Sclerosis</td>
<td>5.0%</td>
<td>0.7%</td>
<td>0.7%</td>
<td>-3.4%</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>2.4%</td>
<td>24.8%</td>
<td>19.9%</td>
<td>12.4%</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>1.8%</td>
<td>-23.6%</td>
<td>-30.0%</td>
<td>-11.2%</td>
</tr>
<tr>
<td>Cystic Fibrosis</td>
<td>0.7%</td>
<td>14.3%</td>
<td>10.1%</td>
<td>-17.9%</td>
</tr>
</tbody>
</table>

By 2020 Autoimmune: Anti-inflammatory, Oncology, and HIV/AIDS will be 65% of specialty cost.

**FIGURE 5**

**Key Specialty Conditions Forecast**

**Specialty Pharmacy Management Solutions**

Consider targeted, whole patient-focused specialty and clinical programs to effectively manage these complex conditions, such as:

- Specialty Distribution
- Site of Service Optimization
- Integrated Care Management
- Medication Therapy Management
Changes in traditional drug costs support containment of overall drug cost

Overall traditional drug costs decreased by 1.8% from 2016 to 2017, but will see a steady decrease through 2020 (see figure 6).

A review of the 2017 traditional trend drivers showed that 2.8% of the trend was driven by higher utilization, while changes in cost drove the trend down by -4.6% (see figure 7).

These traditional drugs are also forecasted to remain relatively stable from 2018 to 2020 (see figure 8).

Looking forward, the following market dynamics contribute to the forecast:

- Diabetes is the largest traditional condition, making up approximately 15.3% of all traditional costs in 2017. From 2018 to 2020, four of the top five traditional drugs are forecasted to be diabetes therapies.
- Generic launches of popular drugs such as Crestor have helped reduce traditional drug trends; however, starting in 2019, there will be fewer patent expirations combined with new pipeline treatments, which are forecasted to result in small traditional drug trend increases.
- Traditional conditions such as dyslipidemia and migraine are starting to see the impact of new pipeline drugs, which will increase costs for conditions that have been stable for the past few years (see figure 9).

\[\text{FIGURE 6} \quad 2017 \text{ Drug Trend}\]

\[\text{FIGURE 7} \quad 2017 \text{ Traditional Trend Drivers}^2\]

\[\text{FIGURE 8} \quad \text{Traditional Drug Trend}\]
From 2017 to 2020, **Dyslipidemia** trend will increase by **60%** primarily due to specialty drugs.
Key Condition Profiles

Autoimmune: Anti-inflammatory

Humira accounts for 50% of condition growth by 2020

MARKET
Oral formulations like Xeljanz XR are expected to make up 10% of cost in 2020. By 2020, the impact of biosimilars for this condition will remain limited due to continued litigation.

PIPELINE
In 2019 and 2020, pipeline drugs will account for between 6% and 12%, respectively, of specialty cost.

HIV/AIDS

Biktarvy will account for 12% of cost in 2020 due to promising efficacy results and decreased side effect profile.

MARKET
Truvada continues to remain as the only drug with a preexposure prophylaxis (PrEP) indication, and will be the top drug for this condition by 2019. Recently approved Juluca will provide fixed-dose combination options for stable patients, thus introducing a new treatment modality for HIV patients.

MARKET
Initially gaining market share, Genovia will lose share to pipeline drugs starting 2019.

Please note that due to rounding, some bar totals do not add up accurately.
**Diabetes**

**Diabetes Market Share Forecast by PMPM**

<table>
<thead>
<tr>
<th>Year</th>
<th>Total</th>
<th>Cost PMPM</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>$11.49</td>
<td>$10.00</td>
<td>(15.3% of total cost)</td>
</tr>
<tr>
<td>2020</td>
<td>$12.16</td>
<td>$12.83</td>
<td>(15.9% of total cost)</td>
</tr>
</tbody>
</table>

**Game Changer**

Trulicity will become the top diabetes drug by 2019 due to more favorable dosing regimen.

**FIGURE 13**

**MARKET**

Trulicity and Jardiance are expected to drive 30-50% of the class growth between 2018 and 2020.

Lantus SoloSTAR will start to lose market share to Toujeo SoloSTAR and Trulicity starting in 2018, but will remain the top insulin product through 2020.

**PIPELINE**

Pipeline impact will be primarily due to oral semaglutide, the first oral GLP-1 receptor agonist expected to come on the market in 2019.

**Dyslipidemia**

**Dyslipidemia Market Share Forecast by PMPM**

<table>
<thead>
<tr>
<th>Year</th>
<th>Total</th>
<th>Cost PMPM</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>$2.04</td>
<td>$2.04</td>
<td>(3.1% of total cost)</td>
</tr>
<tr>
<td>2020</td>
<td>$3.25</td>
<td>$3.25</td>
<td>(4.0% of total cost)</td>
</tr>
</tbody>
</table>

**GAME CHANGERS**

PCSK9s (Repatha and Praluent) will increase condition costs by 65% by 2020.

**FIGURE 14**

**MARKET**

70% of costs in this condition will continue to be generics, such as statins.

**CLINICAL**

Repatha and Praluent are also being studied for monotherapy use.

**PIPELINE**

A third PCSK9, inclisiran, is expected to be released in 2020.

---

Please note that due to rounding, some bar totals do not add up accurately.
Multiple Sclerosis

2017 $3.26 Cost PMPM (5.0% of total cost)
2020 $3.11 Cost PMPM (3.8% of total cost)

**GAME CHANGERS**

Glatiramer acetate (generic Copaxone) and fingolimod (generic Gilenya) will drive cost down in this condition for the first time starting in 2019.

**FIGURE 15**

Multiple Sclerosis Market Share Forecast by PMPM

**MARKET**

Tecfidera is already a market leader in 2018 and will continue to see growth through 2020.

**CLINICAL**

Gilenya will lose patent protection in 2019, increasing generic competition within the condition.

**PIPELINE**

Medical drug Ocrevus will expand the market as the first drug indicated for primary progressive multiple sclerosis.

Hepatitis C

2017 $1.19 Cost PMPM (1.8% of total cost)
2020 $0.67 Cost PMPM (0.8% of total cost)

**IMPACT PLAYER**

Harvoni will remain the top drug for the condition, although the condition will continue to contract.

**FIGURE 16**

Hepatitis C Market Share Forecast by PMPM

**MARKET**

Utilization will continue to decrease as current drugs continue to cure patients.

**CLINICAL**

Mavyret and Vosevi will gain market share due to clinical advantages over Harvoni.

**PIPELINE**

Empty pipeline due to high efficacy rates of current drugs and a smaller patient count.

Please note that due to rounding, some bar totals do not add up accurately.
**Oncology**

<table>
<thead>
<tr>
<th>Year</th>
<th>Total PMPM</th>
<th>% of Total Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>$3.90</td>
<td>(5.9%)</td>
</tr>
<tr>
<td>2020</td>
<td>$5.49</td>
<td>(6.8%)</td>
</tr>
</tbody>
</table>

**Impact Player**

Revlimid continues to be the top oral oncology drug for this condition.

**Figure 17**

**Oncology Market Share Forecast by PMPM**

By 2020, approximately 65 current pipeline drugs will make up 10% of the condition cost.

A robust pipeline of approximately 80 medical drugs will also drive similar costs on the medical benefit.

**Cystic Fibrosis**

<table>
<thead>
<tr>
<th>Year</th>
<th>Total PMPM</th>
<th>% of Total Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>$0.45</td>
<td>(0.7%)</td>
</tr>
<tr>
<td>2020</td>
<td>$0.67</td>
<td>(0.9%)</td>
</tr>
</tbody>
</table>

**Impact Player**

Symdeko pipeline drug will increase condition costs by 50% by 2020.

**Figure 18**

**Cystic Fibrosis Market Share Forecast by PMPM**

Orkambi will remain the market leader through 2020.

**Clinical**

It is estimated that current and future drugs will be able to treat 90% of the cystic fibrosis population by 2019.

**Pipeline**

Pipeline triple-combination therapies to lead the market by 2021.
**Pain: Opioid/Opioid Dependence**

<table>
<thead>
<tr>
<th>Year</th>
<th>Cost PMPM</th>
<th>% of Total Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>$1.18</td>
<td>1.8%</td>
</tr>
<tr>
<td>2020</td>
<td>$0.78</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

**Suboxone** accounted for 18% of the cost for the condition in 2017 and is forecasted to remain the pharmacy benefit market leader through 2020.

**FIGURE 19**

**Pain: Opioid/Opioid Dependence** Market Share Forecast by PMPM

**Pipeline**

Industry is responding with abuse-deterrent formulations of opioids; however, these are expected to have slow growth.

Medical pipeline drug **Sublocade** could change the buprenorphine market and impact pharmacy trend.

**MARKET**

In 2017, the opioid trend decreased nearly 20% due to decreased utilization; this is expected to continue due to increased provider scrutiny.

**Migraine**

<table>
<thead>
<tr>
<th>Year</th>
<th>Cost PMPM</th>
<th>% of Total Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>$0.48</td>
<td>0.7%</td>
</tr>
<tr>
<td>2020</td>
<td>$1.31</td>
<td>1.6%</td>
</tr>
</tbody>
</table>

**Pipeline agent** subcutaneous calcitonin gene-related peptide (CGRP) receptor antagonists are expected to compose 50% of the migraine market.

**FIGURE 20**

**Migraine** Market Share Forecast by PMPM

**MARKET**

Studies suggest 38% to 50% of migraineurs are appropriate CGRP candidates.

**CLINICAL**

More than 37 million Americans suffer from migraine attacks, leading to work absences and loss of productivity.

**PIPELINE**

Current pipeline therapies will increase overall condition costs by 170% by 2020.
Medical Pharmacy Programs

As with all segments, employers are focused on cost-saving measures and programs that help contain the high cost of specialty medications. Medical benefit drugs (provider-administered injectable and infusible drugs) present a unique challenge for employer groups. Employees are dealing with cost-prohibitive conditions such as cancer and autoimmune disorders that require unique medications with few alternative options.

The following data analyzing medical pharmacy benefit programs and management was obtained through a survey conducted with employers from companies ranging in size from 1,000 to more than 1 million employees.

Respondents noted that their medical benefit drug cost was typically less than $10 million and their trend was between 1% and 10%. But two-thirds of respondents (67%) reported 1% to 25% of that medical benefit drug cost was directly related to oncology and oncology-associated supportive drugs (see Key Insights on page 4). Employer groups and their medical benefit managers (pharmacy benefit managers [PBMs], healthcare/pharmacy consultants/brokers) continued to implement strategies and programs to assist in the containment of these costs.

More than half (56%) of employer groups had an official and structured PBM program that managed their drug cost, and 83% of those employer groups were satisfied with that program (see figures 21 and 22). Three quarters (78%) of employer groups had a prior authorization (PA) program in place that managed medical benefit drug use, and these programs were predominantly managed by their PBMs or consultant/brokers (see figures 23 and 24).
Around half of employer groups had input into the listing of drugs included in their PA programs which included up to 50 drugs (see figure 25). PA programs most often included autoimmune drugs, but hemophilia agents, oncology, and oncology support drugs were also high priority (see figure 26).

In addition to PA programs, employer groups implemented care management programs for key categories. Most often (55%) their medical benefit managers implemented care management programs for autoimmune disorders drugs and oncology/oncology support drugs (see figure 27). Additionally and specific to oncology, 43% of employers offered a patient assistance program (see figure 28).

![FIGURE 25](image1)

**2017 Number of Drugs in PA Program**

- 0-10: 29%
- 11-25: 14%
- 26-50: 43%
- >50: 14%

![FIGURE 26](image2)

**2017 Therapeutic Categories Included in PA Program**

- Autoimmune drugs: 55%
- Oncology support: 48%
- Oncology: 45%
- Hemophilia agents: 45%
- Other categories (Drugs >$5,000, niche specialty, rare diseases): 14%
- Other (Botox): 7%

![FIGURE 27](image3)

**2017 Care Management Programs**

- Oncology and oncology support: 55%
- Autoimmune disorders: 65%
- Hemophilia and other blood disorders: 43%
- Other categories (any major illness, heart, diabetes): 21%
- No targeted care management programs: 28%
Medical Pharmacy Management

In addition to management programs, employer group respondents and their medical benefit managers continued to manage the structure of the medical pharmacy benefit. Year over year, coinsurance remained the most common employee contribution, but one-quarter (26%) of employer groups required a co-pay or both co-pay and coinsurance (28%) for employees utilizing medical benefit drugs. Employee coinsurance rates remained stable with an average rate of 38% in 2017 (see figure 29).

Outside of benefit structure, in 2017, employer groups streamlined the number of medical benefit plans they offered their employees from an average of 7.3 in 2016 to 2.5 in 2017. The majority of employee lives (81%) were in administrative services only (ASO) plans, while 19% were in fully insured plans (see figure 30).

Half of employer groups (55%) reported employee out-of-pocket (OOP) co-pays/coinsurance were the same regardless of benefit. But for those employers where there was a cost-share advantage to the member, 57% said the pharmacy benefit had the advantage where as 14% said the medical benefit had advantageous cost-share rates. Close to three-quarters of employer groups (71%) were interested in a solution that would carve out high-cost specialty drugs to a lower cost benefit through their PBM vendor (see figure 31), but only one-third (30%) were approached about the process.

**FIGURE 29**
2017 Employee Medical Benefit Cost Share

<table>
<thead>
<tr>
<th>Co-pay ($) only</th>
<th>Coinsurance (%) only</th>
<th>Require both</th>
<th>Require neither</th>
</tr>
</thead>
<tbody>
<tr>
<td>26%</td>
<td>37%</td>
<td>28%</td>
<td>9%</td>
</tr>
</tbody>
</table>

**FIGURE 30**
2017 Medical Benefit Plan Offerings

<table>
<thead>
<tr>
<th>ASO</th>
<th>Fully insured</th>
</tr>
</thead>
<tbody>
<tr>
<td>81%</td>
<td>19%</td>
</tr>
</tbody>
</table>

Average medical benefit plans dropped from 7.3 in 2016 to 2.5 in 2017.

**FIGURE 31**
Medical versus Pharmacy Benefit

<table>
<thead>
<tr>
<th>Employee OOP Same Across Benefits n=42</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes, pharmacy benefit</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Don’t know</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Benefit with Cost-Share Advantage n=14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes, pharmacy benefit</td>
</tr>
<tr>
<td>Yes, medical benefit</td>
</tr>
<tr>
<td>No advantage</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Considered Carve Out n=42</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
</tbody>
</table>
Administration of medical benefit drugs is often double in the hospital outpatient setting versus the physician office. In 2017, half (55%) of employer groups were providing education to encourage the use of lower cost sites of service for infusion drug treatment, perhaps not active in the process (see figure 32). Even so, 84% of employer groups would offer an incentive to their employees for utilizing lower cost sites of service, including shared cost savings (53%) and higher co-pays for higher cost sites of service (44%) (see figure 33).

Use of technology to track progress of medical benefit drug costs and success of management strategies continued to become more savvy over the last year. In 2017, data reporting to the employer groups from their medical carrier or third-party administrator (TPA) became more common, with 69% of employer groups receiving their total drug cost data and 67% receiving both their year over year drug trend and summary of high-cost drugs captured via drug codes (see figure 34). Frequency of receiving this data varied from monthly to annually. Most frequently, employer groups received their data quarterly (37%) or annually (37%) (see figure 35). Respondents indicated the data was given free of charge to employer groups.

**FIGURE 32**
2017 Utilization of Lower Cost Site of Service

Education on Lower Cost Sites of Service

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>45%</td>
<td>55%</td>
</tr>
</tbody>
</table>

Incentive for Lower Cost Sites of Service

<table>
<thead>
<tr>
<th>Incentive</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>16%</td>
<td>84%</td>
</tr>
</tbody>
</table>

**FIGURE 33**
Incentives to Offer n=36

- Shared cost savings with the member: 53%
- Higher co-pay for higher cost site of service: 44%
- Increased coinsurance for higher cost site of service: 36%
- Other: 17%
- Additional PTO time: 3%

**FIGURE 34**
2017 Medical Benefit Drug Data

Information Provided by Pharmacy Manager n=42

- Total drug cost: 89%
- Annual drug trend year over year: 67%
- Summary of high-cost drugs captured via drug codes: 41%
- Drug cost by disease category: 50%
- Report of utilization data by patient: 33%

**FIGURE 35**
Frequency of Data Report n=38

- Monthly: 14%
- Quarterly: 37%
- Annually: 37%
- Upon request: 3%
Keep on Your Radar

Notable agents that are further from approval have been identified in this unique watch list. These are products with the potential for significant clinical and financial impact. Their development status is being tracked on the MRx Pipeline radar. These pipeline products, their respective class or proposed indication, and an estimated financial forecast for the year 2022 are displayed. The financials are projected total annual U.S. sales, reported in millions.

For more detailed information on the pipeline, please see the latest MRx Pipeline Report on our website.3

Leveraging Innovation and Technology to Advance Healthcare

At Magellan Rx Management, we are committed to leveraging insights from our advanced analytics to uncover new ways to bring value to the clients and members that we serve. We have two divisions within our organization, MRx Studio and Magellan Method, that are focused on challenging the status quo and creating new opportunities that underscore our dedication to innovation. These teams are comprised of internal employees who were selected for their customer focus, creativity, and critical thinking skills. They operate in a fast-paced, autonomous environment with a limited hierarchy structure and are supported across the organization to rapidly ideate and prototype value-driven solutions driven by customer participation and insights. Our devotion to pushing boundaries is just one of the reasons we were ranked #1 in a recent survey for Innovative Services and Programs.4

Our current areas of focus include:

- Adherence Technology
- Cognitive and Digital Therapeutics
- Opioid Use Prevention
- Genomics
- Machine Learning
- Blockchain

Methodology and Disclaimer
All forecasts are based on MRx methodology to project financial impact for years 2018, 2019, 2020 and 2022. Forecasting information is for informational purposes only. This report is based on the following methodology:

- Specialty drugs include only those covered on the pharmacy benefit and are based on MRx specialty definition.
- Cost per claim is based on average wholesale price (AWP), cost = employer liability after cost share.
- Overall drug trend and forecast is based on plan paid per member per month (PMPM) change year over year after rebates and network discounts.
- Specialty drug trend and forecast is based on plan paid PMPM change year over year after rebates and network discounts; individual condition drug trend and forecast is prior to rebate impact but includes network discounts.
- Traditional drug trend and forecast based on plan paid PMPM change year over year after rebates and network discounts; individual condition drug trend and forecast is prior to rebate impact but includes network discounts. Utilization divided into consumers (utilizers) and consumption (days, supply per utilizer).